moderate/high activity patients categorized by DAS28-CRP. The results showed that 1639 (29.9%) remission/low activity patients and 4948 (28.3%) moderate/high activity patients received csDMARD monotherapy, while more combination therapies were prescribed in both groups (57.2% vs 55.1%, respectively). Furthermore, 337 (6.2%) patients received biologic disease-modifying antirheumatic drugs (bDMARDs) in remission/low activity group, while 1021 (5.9%) patients received bDMARDs in moderate/high activity group. In terms of tsDMARDs (only tofacitinib was approved in China), the proportions of usage were lower for remission/ low activity patients (0.2%) than for the moderate/high activity patients (0.3%). On the other hand, the proportion of glucocorticoids usage in remission/low activity patients (15.5%) was lower than in moderate/ high activity patients (21.3%). Conclusion: Over three-quarters of RA patients registered in CREDIT were in moderate/high disease activity. csDMARDs are the most frequently used medications for RA in China.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.